Redeye believes Alelion reported undramatic Q3’20 figures. Sales declined y-o-y due to previously announced reasons, and slightly lower production activity than anticipated due to Covid-19. We believe this is more of a short-term timing effect rather than a long-term issue. Furthermore, very impressive cost reductions were reported, lowering y-o-y OPEX significantly.